Key Highlights
- Mirae Asset Capital Life Science Inception I, LP, a $50 million fund, marks the venture capital firm’s emergence from stealth.
- Investment focus includes therapeutics, diagnostics, AI/ML tools in drug discovery, with core sectors in Oncology, Immunology, Cardiovascular/Metabolic Disease, CNS/Ophthalmology, and Genetic Disease.
- Dr. Naveen M. Krishnan, MD, MPhil, Managing Director, highlights their commitment to advancing life science through strategic investments in biotech companies.
Source: Business Wire
Notable Quote
- “We are honored to have the full support of the Chairman and Mirae Asset in building and growing the U.S. affiliate focused on life science and remain committed to finding the best companies that can bring therapies to patients who need them most.” – Naveen M. Krishnan, MD, MPhil, Managing Director at Mirae Asset Capital Life Science
SoH's Take
The launch of Mirae Asset Capital Life Science’s inaugural fund is a significant development in the venture capital landscape, especially in the biotechnology sector. Their comprehensive investment approach, spanning from seed to Series C in diverse yet critical areas of life science, indicates a strategic and far-reaching vision. With an impressive track record of investing in over 100 biotech companies, including industry giants like BioNTech, Mirae Asset Capital Life Science is well-positioned to make a substantial impact in the U.S. market.
Dr. Naveen M. Krishnan’s experience and leadership further strengthen the firm’s potential to identify and nurture groundbreaking innovations in biotechnology. Their commitment to being an active investor, particularly at the board level, demonstrates a hands-on approach that is likely to benefit their portfolio companies immensely. The focus on AI/ML tools in drug discovery and protein engineering is especially notable, signaling a forward-thinking approach to leveraging technology in healthcare advancements.
Overall, Mirae Asset Capital Life Science’s entrance into the U.S. market with such a robust fund is not just a boon for the biotech sector but also a promising sign for patients awaiting next-generation therapies.
